All NotesCorporate LawIntellectual Property Rights (IPR)

IPR

Topic 158 Healthcare Medical Devices IP

Topic 158 — Healthcare and Medical Devices IP Deep-Dive

HEALTHCARE + MEDICAL DEVICES IP encompasses medical devices (cardiovascular, orthopedic, diagnostic), digital health platforms (telemedicine, electronic health records), AI/ML diagnostic systems, hospital management software, biotech-medical device convergence, healthcare robotics, surgical innovations, drug delivery systems, and emerging technologies (genomics, wearables, IoT-medical). India's healthcare industry is $370 billion (2023) and growing rapidly. Major players include: medical device manufacturers (Becton Dickinson India, Medtronic India, Philips India); hospital chains (Apollo Hospitals, Fortis Healthcare, Manipal); digital health (Practo, 1mg, Pharmeasy, Tata 1mg); diagnostics (Dr. Lal PathLabs, Metropolis Healthcare); telemedicine (eSanjeevani, Practo, Apollo 24/7). The framework integrates: PATENTS ACT 1970 (Section 3(i) medical methods exclusion + Section 3(d) anti-evergreening + Section 3(j) plant/animal exclusion); DRUGS AND COSMETICS ACT 1940 + RULES 1945; MEDICAL DEVICES RULES 2017; CLINICAL ESTABLISHMENTS ACT 2010; INFORMATION TECHNOLOGY ACT 2000 + DPDP ACT 2023 (digital health data); CONSUMER PROTECTION ACT 2019 (medical professional liability); INDIAN MEDICAL COUNCIL ACT 1956. The CENTRAL DRUGS STANDARD CONTROL ORGANISATION (CDSCO) is the regulatory body for medical devices + drugs. SECTION 3(i) is critical — it excludes "any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products". Recent landmark cases: NOVARTIS (2013) Section 3(d) framework; SECTION 3(j) cases for biotech-medical convergence; AVENTIS v. ALGREAT (3 February 2025) ₹5L+4 weeks imprisonment; pharmacovigilance cases; medical device cases. The MEDICAL DEVICES RULES 2017 introduced classification system (Class A/B/C/D risk-based). NDPS ACT 1985 protects against narcotics use. AI/ML medical applications navigate CRI Guidelines 2025 + technical effect framework. This topic walks through every aspect of healthcare + medical devices IP — Section 3(i) framework, medical device patents, digital health, AI medical applications, and recent reforms.

1. Indian Healthcare Industry Framework

A. Industry Scale + Strategic Importance

✅ India's Healthcare Industry

GLOBAL POSITIONING: · $370B+ industry (2023). · Growing rapidly (10%+ CAGR). · 17% of GDP target. · Major medical tourism destination. · Significant emerging-market footprint. MAJOR PLAYERS: · Medical Devices: Becton Dickinson, Medtronic, Philips, Roche. · Hospitals: Apollo, Fortis, Manipal, Max, Narayana. · Diagnostics: Dr. Lal PathLabs, Metropolis, Suburban. · Digital Health: Practo, 1mg, Pharmeasy, Tata 1mg. · Pharmaceuticals: Sun Pharma, Cipla, Lupin, Dr. Reddy's. · Telemedicine: eSanjeevani, Apollo 24/7. · Insurance: HDFC ERGO, Star Health, ICICI Lombard. KEY SEGMENTS: · Medical devices. · Diagnostics. · Hospitals. · Pharmaceuticals. · Digital health (eHealth). · Telemedicine. · Health insurance. · Wellness + preventive. · Genomics + personalized medicine. STRATEGIC IMPORTANCE: · Public health. · Universal Health Coverage. · Foreign exchange (medical tourism). · Innovation + R&D. · Employment generation.

2. Section 3(i) — Medical Methods Exclusion

A. The Statutory Provision

Section 3(i) Patents Act 1970

"3. What are not inventions.—The following are not inventions within the meaning of this Act,— (i) any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products."

B. Application Workshop

✅ Section 3(i) Application Workshop

EXCLUDED: · Medical treatment methods. · Surgical procedures. · Curative methods. · Prophylactic methods (preventive treatment). · Diagnostic methods. · Therapeutic methods. · Animal treatment methods. · Methods to increase animal economic value. NOT EXCLUDED (PATENTABLE): · Medical devices (apparatus). · Pharmaceutical compositions. · Diagnostic kits. · Surgical instruments. · Implants. · Drug delivery systems. · Methods of operating medical devices (sometimes). · In vitro diagnostic methods (typically). CLAIM DRAFTING STRATEGY: · Avoid "method of treating" language. · Frame as APPARATUS for treatment. · Frame as COMPOSITION for use. · Frame as IN VITRO method (where applicable). · Frame as DEVICE comprising specific components. INTERNATIONAL COMPARISON: · EU — broader exception via "human/animal body". · US — methods of treatment generally patentable. · India — strict statutory exclusion. RATIONALE: · Public health priority. · Doctor-patient relationship. · Access to medical care. · Professional autonomy.

C. Medical Device Patentability

  • Apparatus claims protected.
  • Component claims protected.
  • Manufacturing methods protected.
  • Software for devices protected (subject to Section 3(k)).
  • Material innovations protected.
  • Sterilization methods protected.

3. Medical Device Regulatory Framework

A. Medical Devices Rules 2017

✅ Medical Devices Rules 2017

STATUTORY BASIS: · Drugs and Cosmetics Act 1940. · Medical Devices Rules 2017. · Effective 2018. CDSCO REGULATORY STRUCTURE: · Central Drugs Standard Control Organisation. · Drug Controller General of India (DCGI). · State Drug Controllers. MEDICAL DEVICE CLASSIFICATION: · Class A (low risk): bandages, adhesives. · Class B (low-moderate): syringes, gloves. · Class C (moderate-high): X-ray, CT scans. · Class D (high risk): implants, life-support. REGULATORY REQUIREMENTS: · Manufacturing licence. · Import licence. · Registration framework. · Clinical performance evaluation. · Post-marketing surveillance. · Adverse event reporting. NOTIFIED MEDICAL DEVICES: · Specific list under regulation. · Subject to D&C Act provisions. · In-vitro diagnostics (IVDs). CONFORMITY ASSESSMENT: · Conformity Assessment Bodies. · Quality Management System. · ISO 13485 alignment. · Risk management (ISO 14971).

B. Digital Health Framework

  • National Digital Health Mission (NDHM) — Ayushman Bharat Digital Mission.
  • Health Data Management Policy.
  • Electronic Health Records (EHR) standards.
  • Telemedicine Practice Guidelines 2020.
  • Digital Therapeutics framework.
  • Indian Medical Council Act 1956 + Section 35 amendments.

4. AI/ML in Medical Applications

A. AI Diagnostics Framework

✅ AI Medical Applications Workshop

AI MEDICAL APPLICATIONS: · Diagnostic imaging (X-ray, MRI, CT). · Pathology AI (cancer detection). · Clinical decision support. · Drug discovery acceleration. · Personalized medicine. · Health monitoring. · Predictive analytics. · Chatbot medical assistants. IP FRAMEWORK NAVIGATION: 1. PATENT FRAMEWORK · Section 3(k) — software exclusion. · CRI Guidelines 2025 — three-step test. · Section 3(i) — medical method exclusion. · Apparatus claims (medical device approach). · In-vitro diagnostic claims. 2. COPYRIGHT FRAMEWORK · Section 2(o) — software literary work. · Form XIV registration. · Source code protection. 3. DATA PROTECTION · DPDP Act 2023. · Health data special category. · Consent + notification. · Cross-border restrictions. 4. LIABILITY FRAMEWORK · Indian Medical Council Act framework. · Consumer Protection Act 2019. · Professional liability. · Software liability. 5. REGULATORY APPROVAL · CDSCO classification. · Risk-based approach. · Performance evaluation. · Post-marketing surveillance. RECENT DEVELOPMENTS: · AI-powered diagnostics emerging. · Cross-border AI service framework. · DPDP integration. · Telemedicine AI integration.

5. Telemedicine + Digital Health

A. Telemedicine Framework

  • Telemedicine Practice Guidelines 2020 (effective 25 March 2020).
  • Indian Medical Council notified.
  • Doctor-patient consultation framework.
  • Prescription framework.
  • Confidentiality + DPDP integration.
  • Cross-border teleconsultation.

B. Digital Health Platforms

  • Practo — telemedicine platform.
  • 1mg (Tata 1mg) — pharmacy + diagnostics.
  • Pharmeasy — pharmacy + diagnostics.
  • Apollo 24/7 — hospital chain telemedicine.
  • eSanjeevani — government national telemedicine.
  • mfine — AI-powered consultation.
  • DocTalk — clinical communication.

C. Health Data Management

  • Ayushman Bharat Digital Mission.
  • Health Data Management Policy.
  • Personal Health Records.
  • Cross-institution data sharing framework.
  • Patient consent management.
  • DPDP Act 2023 integration.

6. Notable Healthcare IP Cases

📖 Aventis Pharma v. Algreat Industries, 3 February 2025

Background — Pharmaceutical patent enforcement.

Holding — ₹5L damages + 4 weeks imprisonment.

Significance — Strong pharma enforcement framework.

📖 Novartis AG v. Union of India, (2013) 6 SCC 1

Background — Glivec/Imatinib mesylate beta-crystalline form.

Holding — Section 3(d) strict therapeutic efficacy test.

Significance — Cornerstone Indian pharma jurisprudence.

📖 Natco v. Bayer, 2012 (Patent Office)

Background — Sorafenib compulsory licensing.

Holding — First Section 84 grant; 6% royalty.

Significance — Compulsory licensing framework.

7. Strategic Considerations

✅ For healthcare companies — eight points

For medical devices, frame as apparatus claims (avoid Section 3(i)).

For pharmaceuticals, navigate Section 3(d) with therapeutic efficacy.

For AI medical applications, leverage CRI Guidelines 2025 + medical device framework.

For digital health, integrate DPDP Act 2023 (effective February 2025).

For telemedicine, leverage 2020 Guidelines + IMC Act framework.

For data protection, ensure health data special category compliance.

For regulatory, navigate CDSCO classification + clinical evaluation.

For enforcement, leverage Aventis 2025 framework.

8. Memory Aid — Quick Recall

✅ Quick Recall — Healthcare IP

India healthcare: $370B; growing 10%+ CAGR.

Section 3(i) — medical/surgical/curative/prophylactic/diagnostic methods NOT patentable.

Apparatus + composition claims patentable.

Drugs and Cosmetics Act 1940 + Rules 1945.

Medical Devices Rules 2017 — Class A/B/C/D risk-based.

CDSCO — Central Drugs Standard Control Organisation.

Telemedicine Practice Guidelines 2020 (effective 25 March 2020).

Ayushman Bharat Digital Mission framework.

CRI Guidelines 2025 — for AI medical applications.

DPDP Act 2023 — health data special category (effective February 2025).

Section 3(d) — anti-evergreening (Novartis 2013).

Section 84 — compulsory licensing (Natco-Bayer 2012).

Section 107A — Bolar exception (Bayer-UoI 2019).

Aventis 2025 — ₹5L + 4 weeks imprisonment.

🎯 EXAM POINTERS — TOPIC 158

  • Indian healthcare industry: $370B (2023); growing 10%+ CAGR.
  • Section 3(i) Patents Act — medical/surgical/curative/prophylactic/diagnostic/therapeutic methods NOT patentable.
  • Section 3(i) — also excludes animal treatment methods.
  • Section 3(d) Patents Act — anti-evergreening for pharmaceuticals.
  • Section 3(j) — plant/animal exclusion (relevant for biotech-medical convergence).
  • Drugs and Cosmetics Act 1940 + Drugs and Cosmetics Rules 1945.
  • Medical Devices Rules 2017 — Class A (low) / B / C / D (high) risk classification.
  • CDSCO — Central Drugs Standard Control Organisation.
  • DCGI — Drug Controller General of India.
  • Notified Medical Devices framework.
  • Telemedicine Practice Guidelines 2020 — effective 25 March 2020.
  • Indian Medical Council Act 1956 — professional registration framework.
  • Ayushman Bharat Digital Mission — National Digital Health Mission.
  • Health Data Management Policy framework.
  • Electronic Health Records (EHR) standards.
  • CRI Guidelines 2025 — AI medical application framework.
  • DPDP Act 2023 — health data SPECIAL CATEGORY (effective February 2025).
  • Consumer Protection Act 2019 — professional liability framework.
  • Novartis AG v. Union of India (2013 6 SCC 1) — Section 3(d) framework.
  • Natco v. Bayer (Patent Office 2012) — Section 84 compulsory licensing; Sorafenib; 6% royalty.
  • Bayer v. UoI (LPA 359/2017; Del HC 2019) — Section 107A Bolar broad.
  • Aventis v. Algreat (3 February 2025 Del HC) — ₹5L + 4 weeks imprisonment.
  • Drug Price Control Order (DPCO) 2013 — pricing framework.
  • Essential Commodities Act 1955 Section 3 — DPCO statutory basis.
  • NLEM — National List of Essential Medicines.
  • NDPS Act 1985 — narcotics framework.
  • Doha Declaration 2001; MC12 Decision 2022 — India lead role.